Prophylaxis use among males with haemophilia B in the United States.

about

Prophylaxis use among males with haemophilia B in the United States.

Item

http://www.wikidata.org/entity/Q38638489

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prophylaxis use among males with haemophilia B in the United States.

@en

type

Item

label

Prophylaxis use among males with haemophilia B in the United States.

@en

prefLabel

Prophylaxis use among males with haemophilia B in the United States.

@en

P1476

Prophylaxis use among males with haemophilia B in the United States

@en

P2093

Hemophilia Treatment Center Network Investigators

http://www.w3.org/2001/XMLSchema#string

J M Soucie

http://www.w3.org/2001/XMLSchema#string

M Recht

http://www.w3.org/2001/XMLSchema#string

Q C Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010

An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.

The universal data collection surveillance system for rare bleeding disorders.

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.

The changing prognosis of classic hemophilia (factor VIII "deficiency").

Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.

Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.

Insufficient evidence to suggest less stringent therapy in hemophilia B?

Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.

Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications.

P304

910-917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13317

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Scott D Grosse

M Ullman

P577

2017-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28780772

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia B

P932

5724962

http://www.w3.org/2001/XMLSchema#string